Autism Spectrum Disorders Market Size, Share, Competitive Landscape and Trend Analysis Report, by Disease, by Service, by Location : Global Opportunity Analysis and Industry Forecast, 2021-2031

Autism Spectrum Disorders Market Research, 2031

The global autism spectrum disorders market was valued at $27.3 billion in 2021, and is projected to reach $43.2 billion by 2031, growing at a CAGR of 4.6% from 2022 to 2031. Autism spectrum disorder (ASD) is a developmental disability caused by differences in the brain. Some people with autism spectrum disorder (ASD) have a known difference, such as a genetic condition. Other causes are not yet known. Scientists believe there are multiple causes of autism spectrum disorder (ASD) that act together to change the most common ways people develop. The autism spectrum disorder (ASD) includes multiple disorders such as autistic disorder, Asperger’s syndrome, pervasive development disorder (PDD).

The increase in the prevalence of autism spectrum disorder (ASD) and the rise in the diagnosis rate of autism spectrum disorder (ASD) drive the Autism Spectrum Disorders Market Growth. For instance, in March 2022, as per the report of World Health Organization (WHO), it is estimated that worldwide about one in 100 children has autism spectrum disorder. The early diagnosis of autism spectrum disorder (ASD) plays a vital role in understanding and managing of the disorder. Various studies have found the average age of diagnosis to be between 3 and 6 years, with significant differences as a function of ethnicity and socio-economic status.

Moreover, an increase in R&D activity for advancements in autism spectrum disorder treatment, latest product launch and product approvals contributes to the growth of the Autism Spectrum Disorders Industry. For instance, in June 2021, Cognoa, a pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with behavioral health conditions, received approval from the U.S. Food and Drug Administration (FDA) for its De Novo classification request for its autism diagnosis aid. The AI-based device is the first FDA-authorized diagnosis aid designed to help physicians to diagnose autism in the primary care setting.

The growth in interest of manufacturers & developers in the development of autism spectrum disorder treatment drives the growth of the Autism Spectrum Disorders Industry. In addition, combined manufacturers' efforts for developing footprints in emerging market contributes in the growth of the Autism Spectrum Disorders Market Size. In addition, an increase in funding by government and non-government organizations propels the growth of the market. For instance, in March 2022, Rare Cannabinoid Company, a leading CBD and hemp cannabinoid company in the U.S. announced its support for the Autism Summit April 2022, in the form of sponsorship and donation of CBD and CBDV oil products.

Furthermore, growth in advancements in biotechnology, an increase in access to health care facilities globally, and surge in health care expenditure drive the growth of the Autism Spectrum Disorders Market Size. For instance, according to American Medical Association (AMA), health spending in the U.S. increased by 9.7% in 2020 to $4.1 trillion or $12,530 per capita. Moreover, rise in the government initiatives to provide advanced healthcare facilities and financial support propels the growth of the market.

The autism spectrum disorders market is segmented into Disease, Service, and Location.

By service, the market is classified into behavioral approaches, early intervention, medication, and others. Depending on the disease, the market is fragmented into autistic disorder, Asperger’s syndrome, and pervasive development disorder (PDD). By location, the market is categorized into hospitals, education counselor centers, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Arabia, South Africa, and LAMEA).

On the basis of the disease segment, the autistic disorder segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to a surge in incidences of autistic disorder and a rise in the preterm birth rate. However, the Asperger’s syndrome segment is expected to witness considerable growth during the forecast period due to an increase in incidences of Asperger’s syndrome and the latest product approvals.  

Depending on the service segment, the behavioral approaches segment dominated the Autism Spectrum Disorders Market Share in 2021, and this trend is expected to continue during the forecast period, owing to increasing improvements in behavioral approaches and rise in awareness about autism spectrum diseases. However, the medication segment is expected to witness considerable growth during the forecast period, due to an increase in awareness about early diagnosis of autism spectrum disorders and a rise in healthcare expenditures.

By location, the education counselor center segment dominated the Autism Spectrum Disorders Market Share in 2021, and this trend is expected to continue during the Autism Spectrum Disorders Market Forecast period, owing to rise in a number of education counselor centers and an increase in demand of advanced treatment. However, the hospital segment is expected to witness considerable growth during the forecast period, due to an upsurge in a number of hospitals and rise in healthcare expenditure.

By region, North America garnered the major share in the autism spectrum disorder treatment market in 2021, and is expected to dominate the global market during the forecast period owing to an increase in a product launches in region, well-established healthcare infrastructure, and the presence of key players. However, Asia-Pacific is expected to register significant growth, owing to a rise in healthcare expenditures, development in healthcare infrastructure, and high population base.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the autism spectrum disorders market analysis from 2021 to 2031 to identify the prevailing Autism Spectrum Disorders Market Opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the autism spectrum disorders market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global autism spectrum disorders market trends, key players, market segments, application areas, and market growth strategies.

  Autism Spectrum Disorders Market Report Highlights

Aspects	Details
Market Size By 2031	USD 43.2 billion
Growth Rate	CAGR of 4.6%
Forecast period	2021 - 2031
Report Pages	300
By Disease	Autistic Disorder Asperger Syndrome Pervasive development disorder (PDD) Other
By Service	Behavioural Approaches Gender Male Female Early Intervention Gender Male Female Medication Gender Male Female Other Services Gender Male Female
By Location	Hospitals Education Counsellor Center Others
By Region	North America  (U.S., Canada, Mexico) Europe  (Germany, France, UK, Italy, Spain, Rest of Europe) Asia-Pacific  (Japan, China, Australia, India, Rest of Asia-Pacific) LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players	Bristol Myers Squibb Co., Abbvie Inc, Curemark LLC, Cognoa Inc, EarliTec Diagnostics Inc, dfusion inc., Novartis AG, Jazz Pharmaceuticals, Johnson & Johnson, Axial therapeutics

Analyst Review

This section provides the opinions of the top level CXOs in the autism spectrum disorder treatment market. According to the CXOs, autism spectrum disorder is a group of neurological disorders mainly characterized by difficulty in social interaction and social communication with repetitive or restricted pattern of daily activities. 

The autism spectrum disorder treatment mainly includes behavioral approaches, early intervention, medication and others.

The factors such as increase in prevalence of autism spectrum disorders, advancements in autism spectrum disorder treatment, and surge in demand of early diagnosis of disease drives the growth of autism spectrum disorder treatment market. In addition, increase in birth rate and rise in healthcare expenditures of patients are expected to contribute in the growth of the autism spectrum disorder treatment market.

North America is expected to witness the highest growth, in terms of revenue, owing to rise in the prevalence of autism spectrum disorder, the presence of key players for manufacturing & development of advanced autism spectrum disorder treatments, and well-established healthcare infrastructure in the region.

However, the high operational cost of autism spectrum disorder treatment and lack of awareness about disease may hamper market growth.

Author Name(s) : Prathmesh Santosh Bhasme | Roshan Deshmukh

Related Tags

• Neurological Disorders
• Neurology
• Mental Disorder

^*Terms and Conditions Apply